Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
ENCO On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

encorium group inc (ENCO) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENCORIUM GROUP INC (ENCO)

Related News

No related news articles were found.

encorium group inc (ENCO) Related Businessweek News

No Related Businessweek News Found

encorium group inc (ENCO) Details

Encorium Group, Inc. engages in the design and management of clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe. The company’s clinical research and development services supporting Phase I through Phase IV clinical trials include study protocol design services; clinical trials management services, such as case report form design, investigator recruitment, patient enrollment, and study monitoring and data collection; data management services comprising case report form review and tracking, data entry, clinical/statistical reports, and writing manuscripts for publication; biostatistics services that assist in the development and review of protocols, design of analysis plans, and design of report formats. Its services also include medical and regulatory services comprising regulatory strategy formulation, new drug application, biologic license application document preparation and review, and quality assurance and liaison with the FDA and other regulatory agencies; quality assurance and compliance services, such as conducting investigator audits, pre-submission protocol compliance audits, and GCP audits; and report writing services, such as presenting statistical analysis findings for data collected during the trial with other clinical data in study form to clients, or to the FDA or other regulatory agencies, as well as patient registries, which populate databases with patient-derived information to analyze and disseminate in various formats. The company offers its services in various therapeutic areas, such as cardiovascular, endocrinology/metabolism, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, women’s health, and respiratory medicine. The company was formerly known as Covalent Group, Inc. and changed its name to Encorium Group, Inc. in November 2006. The company was founded in 1989 and is based in Wayne, Pennsylvania.

141 Employees
Last Reported Date: 10/3/11
Founded in 1989

encorium group inc (ENCO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
President of Corporate and Business Developme...
Total Annual Compensation: --
Senior Vice President of Clinical Operations
Total Annual Compensation: --
Executive Vice President
Total Annual Compensation: --
Principal Accounting Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

encorium group inc (ENCO) Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against Encorium Group Inc. For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Encorium Group Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENCO:US $0.00 USD 0.00

ENCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENCO.
View Industry Companies

Industry Analysis


Industry Average

Valuation ENCO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENCORIUM GROUP INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at